This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wasnich, R. D. Articles by Miller, P. D. Search for Related Content PubMed PubMed Citation Articles by Wasnich, R. D. Articles by Miller, P. D.

Antifracture Efficacy of Antiresorptive Agents Are Related to Changes in Bone Density

Hawaii Osteoporosis Center (R.D.W.), Honolulu, Hawaii 96814; and Colorado Center for Bone Research (P.D.M.), Lakewood, Colorado 80227

There is a current debate about the extent to which antifracture efficacy of antiresorptive drugs are related to changes in bone mineral density (BMD). In vitro studies show that most of the variability in bone strength is related to BMD, and prospective studies have shown that low BMD is an important predictor of fracture risk. It seems that higher levels of bone turnover are also associated with increased fracture risk. Over the short term, a reduction in activation frequency or resorption depth would lead to fewer (and/or shallower) resorption sites and refilling of existing sites initially. There is also evidence that inhibiting resorption allows bone to respond to mechanical demands, preferentially thickening critical trabeculae, and this may help compensate for reduced connectivity. Each of these mechanisms would increase BMD and would disproportionately improve bone strength. Over the long term, maintaining bone mass and preventing loss of structural elements would result in progressively greater differences in BMD and fracture risk over time, relative to untreated women. The conceptual model predicts that both the short- and long-term antifracture efficacy of antiresorptive drugs will depend on the extent to which treatment can increase and maintain BMD. To examine this issue, we compiled data from clinical trials of antiresorptive agents and plotted the relative risk of vertebral fractures against the average change in BMD for each trial. The confidence intervals are large for individual trials, and there was substantial variability in antifracture efficacy at any given level of change in BMD. Overall, however, trials that reported larger increases in BMD tended to observe greater reductions in vertebral fracture risk. Poisson regression was used to quantify this relationship. The model predicts that treatments that increase spine BMD by 8% would reduce risk by 54%; most of the total effect of treatment was explained by the 8% increase in BMD (41% risk reduction). These findings are consistent with the short-term predictions of the conceptual model and with reports from randomized trials. The small but significant reductions in risk that were not explained by measurable changes in BMD might be related to publication bias, measurement errors, or limitations of current BMD technology.

This article has been cited by other articles:

				O. Bruyere, C. Roux, J. Detilleux, D. O. Slosman, T. D. Spector, P. Fardellone, K. Brixen, J.-P. Devogelaer, M. Diaz-Curiel, C. Albanese, et al. Relationship between Bone Mineral Density Changes and Fracture Risk Reduction in Patients Treated with Strontium Ranelate J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3076 - 3081. [Abstract] [Full Text] [PDF]

				M. E. Kraenzlin Biochemical Markers of Bone Turnover and Osteoporosis Management IBMS BoneKEy, July 1, 2007; 4(7): 191 - 203. [Abstract] [Full Text] [PDF]

				P. F. Lata and M. E. Elliott Patient Assessment in the Diagnosis, Prevention, and Treatment of Osteoporosis Nutr Clin Pract, June 1, 2007; 22(3): 261 - 275. [Abstract] [Full Text] [PDF]

				M. Ferrone and M. Geraci A Review of the Relationship Between Parenteral Nutrition and Metabolic Bone Disease Nutr Clin Pract, June 1, 2007; 22(3): 329 - 339. [Abstract] [Full Text] [PDF]

				M. Raman, E. Aghdassi, M. Baun, M. Yeung, L. Fairholm, O. Saqui, and J. P. Allard Metabolic Bone Disease in Patients Receiving Home Parenteral Nutrition: A Canadian Study and Review JPEN J Parenter Enteral Nutr, November 1, 2006; 30(6): 492 - 496. [Abstract] [Full Text] [PDF]

				S. Bonnick, K. G. Saag, D. P. Kiel, M. McClung, M. Hochberg, S.-A. M. Burnett, A. Sebba, R. Kagan, E. Chen, D. E. Thompson, et al. Comparison of Weekly Treatment of Postmenopausal Osteoporosis with Alendronate Versus Risedronate Over Two Years J. Clin. Endocrinol. Metab., July 1, 2006; 91(7): 2631 - 2637. [Abstract] [Full Text] [PDF]

				J-Y Reginster, S Adami, P Lakatos, M Greenwald, J J Stepan, S L Silverman, C Christiansen, L Rowell, N Mairon, B Bonvoisin, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study Ann Rheum Dis, May 1, 2006; 65(5): 654 - 661. [Abstract] [Full Text] [PDF]

				D.J. Hosking, P. Geusens, and R. Rizzoli Osteoporosis therapy: an example of putting evidence-based medicine into clinical practice QJM, June 1, 2005; 98(6): 403 - 413. [Abstract] [Full Text] [PDF]

				A. L. Buchman Population-Based Screening for Celiac Disease: Improvement in Morbidity and Mortality From Osteoporosis? Arch Intern Med, February 28, 2005; 165(4): 370 - 372. [Full Text] [PDF]

				I. R. Reid, R. Eastell, I. Fogelman, J. D. Adachi, A. Rosen, C. Netelenbos, N. B. Watts, E. Seeman, A. V. Ciaccia, and M. W. Draper A Comparison of the Effects of Raloxifene and Conjugated Equine Estrogen on Bone and Lipids in Healthy Postmenopausal Women Arch Intern Med, April 26, 2004; 164(8): 871 - 879. [Abstract] [Full Text] [PDF]

				H. G. Bone, D. Hosking, J.-P. Devogelaer, J. R. Tucci, R. D. Emkey, R. P. Tonino, J. A. Rodriguez-Portales, R. W. Downs, J. Gupta, A. C. Santora, et al. Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women N. Engl. J. Med., March 18, 2004; 350(12): 1189 - 1199. [Abstract] [Full Text] [PDF]

				J. A. Clowes, N. F. A. Peel, and R. Eastell The Impact of Monitoring on Adherence and Persistence with Antiresorptive Treatment for Postmenopausal Osteoporosis: A Randomized Controlled Trial J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1117 - 1123. [Abstract] [Full Text] [PDF]

				F. E. Vegni, C. Corradini, G. Privitera, T. Sugiyama, H. Tanaka, S. Kawai, P. D. Miller, K. E. Fuller, D. M. Black, J. Bilezikian, et al. Effects of Parathyroid Hormone and Alendronate Alone or in Combination in Osteoporosis N. Engl. J. Med., January 8, 2004; 350(2): 189 - 192. [Full Text] [PDF]

				S. L. Greenspan, N. M. Resnick, and R. A. Parker Combination Therapy With Hormone Replacement and Alendronate for Prevention of Bone Loss in Elderly Women: A Randomized Controlled Trial JAMA, May 21, 2003; 289(19): 2525 - 2533. [Abstract] [Full Text] [PDF]

				N. B. Watts, R. G. Josse, R. C. Hamdy, R. A. Hughes, M. D. Manhart, I. Barton, D. Calligeros, and D. Felsenberg Risedronate Prevents New Vertebral Fractures in Postmenopausal Women at High Risk J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 542 - 549. [Abstract] [Full Text] [PDF]

				S. L. Greenspan, R. D. Emkey, H. G. Bone III, S. R. Weiss, N. H. Bell, R. W. Downs Jr., C. McKeever, S. S. Miller, M. Davidson, M. A. Bolognese, et al. Significant Differential Effects of Alendronate, Estrogen, or Combination Therapy on the Rate of Bone Loss after Discontinuation of Treatment of Postmenopausal Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled Trial Ann Intern Med, December 3, 2002; 137(11): 875 - 883. [Abstract] [Full Text] [PDF]

				A. Cranney, G. Guyatt, L. Griffith, G. Wells, P. Tugwell, and C. Rosen IX: Summary of Meta-Analyses of Therapies for Postmenopausal Osteoporosis Endocr. Rev., August 1, 2002; 23(4): 570 - 578. [Full Text] [PDF]

				S. Palomba, F. Orio Jr., A. Colao, C. di Carlo, T. Sena, G. Lombardi, F. Zullo, and P. Mastrantonio Effect of Estrogen Replacement Plus Low-Dose Alendronate Treatment on Bone Density in Surgically Postmenopausal Women with Osteoporosis J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1502 - 1508. [Abstract] [Full Text] [PDF]

				M. C. Hochberg, S. Greenspan, R. D. Wasnich, P. Miller, D. E. Thompson, and P. D. Ross Changes in Bone Density and Turnover Explain the Reductions in Incidence of Nonvertebral Fractures that Occur during Treatment with Antiresorptive Agents J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1586 - 1592. [Abstract] [Full Text] [PDF]

				R. Marcus, M. Wong, H. Heath III, and J. L. Stock Antiresorptive Treatment of Postmenopausal Osteoporosis: Comparison of Study Designs and Outcomes in Large Clinical Trials with Fracture as an Endpoint Endocr. Rev., February 1, 2002; 23(1): 16 - 37. [Abstract] [Full Text] [PDF]

				T. J Wilkin, D. Devendra, J. Dequeker, and F. P Luyten For and against: Bone densitometry is not a good predictor of hip fracture For Against BMJ, October 6, 2001; 323(7316): 795 - 799. [Full Text] [PDF]

				J. C. Prior, S. A. Kirkland, L. Joseph, N. Kreiger, T. M. Murray, D. A. Hanley, J. D. Adachi, Y. M. Vigna, C. Berger, L. Blondeau, et al. Oral contraceptive use and bone mineral density in premenopausal women: cross-sectional, population-based data from the Canadian Multicentre Osteoporosis Study Can. Med. Assoc. J., October 1, 2001; 165(8): 1023 - 1029. [Abstract] [Full Text] [PDF]

				Bisphosphonates for osteoporosis DTB, September 1, 2001; 39(9): 68 - 72. [Abstract] [Full Text] [PDF]

				S. A. Stoch, R. A. Parker, L. Chen, G. Bubley, Y.-J. Ko, A. Vincelette, and S. L. Greenspan Bone Loss in Men with Prostate Cancer Treated with Gonadotropin-Releasing Hormone Agonists J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2787 - 2791. [Abstract] [Full Text] [PDF]

				V. Kantorovich, M. A. Gacad, L. L. Seeger, and J. S. Adams Bone Mineral Density Increases with Vitamin D Repletion in Patients with Coexistent Vitamin D Insufficiency and Primary Hyperparathyroidism J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3541 - 3543. [Abstract] [Full Text]

				R. P. Tonino, P. J. Meunier, R. Emkey, J. A. Rodriguez-Portales, C.-J. Menkes, R. D. Wasnich, H. G. Bone, A. C. Santora, M. Wu, R. Desai, et al. Skeletal Benefits of Alendronate: 7-Year Treatment of Postmenopausal Osteoporotic Women J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3109 - 3115. [Abstract] [Full Text]

				P. Ravn, R. D. Wasnich, and G. Cizza Long-Term Prevention of Bone Loss Ann Intern Med, July 4, 2000; 133(1): 72 - 73. [Full Text] [PDF]